Ohkubo Atsushi, Sakurasawa Takatoshi, Hoshikawa Yuki, Deushi Masaya, Usui Mana, Komori Shigeto, Itagaki Ayako, Yamamoto Hiroko, Seshima Hiroshi, Kurashima Naoki, Iimori Soichiro, Naito Shotaro
Medical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Department of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Ther Apher Dial. 2025 Aug;29(4):588-592. doi: 10.1111/1744-9987.70024. Epub 2025 Apr 14.
Rheocarna has attracted attention as an alternative therapy for severe chronic limb-threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non-dialysis patients.
Four non-dialysis patients who received Rheocarna were studied to determine the conditions under which it was administered and its effectiveness.
The ulcer healed completely, but two patients required skin grafting. The treatment time and blood flow rate were 90-120 min and 50-80 mL/min, respectively. The processed volume was about 1.0 times the circulating blood volume, and the removal rate of low-density lipoprotein and fibrinogen was about 10%-15%.
The ulcers healed despite the removal rate of low-density lipoprotein and fibrinogen being small. To our knowledge, this is the first report on the treatment conditions and effectiveness of Rheocarna in non-dialysis patients.
流变血液吸附疗法（Rheocarna）作为治疗严重慢性肢体威胁性缺血的一种替代疗法已引起关注，并且已有关于其有效性的报道。然而，这些报道大多针对透析患者，关于非透析患者的治疗条件和疗效的报道较少。
对4例接受流变血液吸附疗法的非透析患者进行研究，以确定治疗实施的条件及其有效性。
溃疡完全愈合，但2例患者需要进行皮肤移植。治疗时间和血流速度分别为90 - 120分钟和50 - 80毫升/分钟。处理量约为循环血量的1.0倍，低密度脂蛋白和纤维蛋白原的清除率约为10% - 15%。
尽管低密度脂蛋白和纤维蛋白原的清除率较低，但溃疡仍愈合。据我们所知，这是关于流变血液吸附疗法在非透析患者中的治疗条件和有效性的首次报道。
